URALCHEM
and a leading Latvian charity organization, the Ziedot.lv Fund, held
New Year activities and events for a group of seriously ill children
in Latvia and members of their families. URALCHEM's CEO, Dmitry
Konyaev, and the head of the Ziedot.lv Fund, Ruta Dimanta, gave
presents to the children.
Riga,
Latvia - December 20, 2012 -- URALCHEM
and a leading Latvian charity organization, the Ziedot.lv
Fund, held New Year activities and events for a group of seriously
ill children in Latvia and members of their families. URALCHEM's CEO,
Dmitry Konyaev, and the head of the Ziedot.lv Fund, Ruta Dimanta,
gave presents to the children. These children are beneficiaries of a
joint charity programme "Help for seriously ill children",
which was launched in the autumn of this year.
In
September 2012, URALCHEM and the Ziedot.lv Fund signed an agreement
that started a charitable programme for the treatment of 20 children
from Latvia in leading Russian clinics. URALCHEM is providing total
funding to the amount of €80 thousand.
Since
the launch of the programme, 11 families have received help with
specific treatment or rehabilitation for their children using leading
Russian clinics. The Ziedot.lv Fund has selected clinics and
treatment programmes on the basis of doctors' recommendations and
requests from parents for financial assistance. URALCHEM has
currently provided €25 thousand of funding.
Dmitry
Konyaev came to Latvia to show his support for the children and give
them New Year presents. "We are pleased that the company's
social policy in Latvia is generating results already. Together with
the Ziedot.lv Fund, we intend to continue our support for the
children. They are now on their way to recovery and I wish them
success in the coming year in overcoming their problems," he
said.
Ruta
Dimanta said that the Fund treated every case individually, choosing
leading medical institutions in Russia to carry out the treatments.
In clinical cases involving children with rare or complex conditions
requiring care outside Latvia and not funded by the state, URALCHEM's
participation enables the provision of hospital and other treatment
and support for the children's' families. She added, "The
condition of the children who have been helped has improved
significantly. We are grateful to the Russian doctors and to URALCHEM
for their assistance. Our joint programme is gaining momentum and I
hope that as a result, next year more families will be able to
celebrate this holiday with joy."
-Ends-
Public
Relations Department
URALCHEM,
OJSC
Tel:
+7 (495) 721 89 89
E-Mail:
pr@URALCHEM.com
URALCHEM,
OJSC is one of the largest producers of nitrogen and phosphate
fertilisers in Russia and the CIS with production capacities of over
2.5 million tonnes of ammonium nitrate, 2.8 million tonnes of
ammonia, 0.8 million tonnes of MAP and DAP, 0.8 million tonnes of
complex fertilisers and 1.2 million tonnes of urea. URALCHEM, OJSC is
the second largest ammonium nitrate producer in the world and number
one in Russia, the second largest producer of nitrogen fertilisers in
Russia. Key production assets of URALCHEM, OJSC include Azot Branch
of URALCHEM, OJSC in Berezniki, Perm Region; OJSC Minudobrenia, Perm;
MFP Kirovo-Chepetsk Chemical Works, OJSC Branch in Kirovo-Chepetsk,
Kirov region; Voskresensk Mineral Fertilisers, OJSC in Voskresensk,
Moscow region.
Some
of the information in this press release may contain projections or
other forward-looking statements regarding future events or the
future financial performance of URALCHEM. We wish to caution you that
these statements are only predictions. We do not intend to update
these statements and our actual results may differ materially from
those contained in our projections or forward-looking statements,
including, among others, the achievement of anticipated levels of
profitability, growth, cost and synergy of our recent acquisitions,
the impact of competitive pricing, the ability to obtain necessary
regulatory approvals and licenses, the impact of developments in the
Russian economic, political and legal environment, financial risk
management and the impact of general business and global economic
conditions.
